Growth Hormone-Releasing Hormone

Phase 3Small molecule

Growth Hormone-Releasing Hormone is one of 61 small molecule programs targeting Growth Hormone Deficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Growth Hormone DeficiencyActive, not recruiting

GrowthActive, not recruiting

Growth Hormone DeficiencyPreclinical

Active, not recruiting

GrowthPhase 3

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Growth Hormone-Releasing Hormone

MMassachusetts General Hospital

Phase 3

2 3

Lenvima

Eisai

Preclinical

1 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Somavaratan

Glucophage

2 9

Neupogen

EEastern Cooperative Oncology Group

Preclinical

1 10

Glucagon

XXeris Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth2 trials

Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response

Unknown status·—·Phase 3·NCT02736591·210 enrolled

Effects of Short-term Growth Hormone in HIV-infected Patients

Completed·MMassachusetts General Hospital·N/A·NCT00795210·25 enrolled

Growth Hormone Deficiency1 trial

Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)

Completed·SStefania La Grutta, MD··NCT02507245·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Growth Hormone-Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Growth Hormone-Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Growth Hormone-Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

Growth Hormone-Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth2 trials

Growth Hormone Deficiency1 trial

References

Drug Info

Quick Facts

Related News